A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

Exclusion Criteria

• •Evidence of inadequate organ function during the screening period
• •Active central nervous system (CNS) symptoms attributable to autoimmune disease within 12 months prior to trial intervention
• •History of or current renal diseases (other than LN) that, in the opinion of the investigator, could interfere with assessment of LN or confound evaluation of disease activity
• •Receipt of dialysis (hemodialysis or peritoneal dialysis) within 12 weeks of trial intervention
• •Irreversible organ damage related to underlying disease (e.g., ESRD) where, in the opinion of the investigator, CD19 CAR T-cell therapy would be unlikely to benefit the participant
• •History of malignancy in the prior 5 years
• •Known allergy to the following FT819 components: albumin (human) or DMSO
• •History of intolerance or contraindication to bendamustine
• •Body weight \<30 kg
• •Any medical condition, clinical laboratory abnormality, or nonmedical/social issue that, per investigator or medical monitor judgement, precludes safe participation in and completion of the trial or that could affect compliance with protocol conduct or interpretation of results